GENE ONLINE|News &
Opinion
Blog

The Architects of Memory and Movement: Who Is Building the Future of Brain Disease Treatment

by Bernice Lottering
Share To
A handful of pharmaceutical giants — along with a growing cohort of biotechs — have staked their pipelines on Alzheimer's and Parkinson's. Their strategies differ. Their ambitions do not. Image: Shutterstock
More than 55 million people worldwide live with dementia, and nearly 12 million carry a Parkinson’s diagnosis — figures that the World Health Organization projects …

The Architects of Memory and Movement: Who Is Building the Future of Brain Disease Treatment Read More »

It's free! Log in now to read

LATEST
YEARS Diagnostic Algorithm Reduces CTPA Scans by Over 20 Percent in Cancer Patients
2026-07-12
West Nile and Usutu Viruses Detected in Wild Carnivore Populations in the Netherlands
2026-07-11
Norwegian Stakeholders Identify Implementation Challenges in Elder Abuse Prevention Guidelines for 2026 BMC Geriatrics Study
2026-07-11
Norwegian Stakeholders Identify Implementation Challenges in Elder Abuse Prevention Guidelines for 2026 BMC Geriatrics Study
2026-07-11
Biotech Stock Performance Gap Widens During Second Quarter of 2026
2026-07-11
PYGO2 Overexpression Linked to Increased Plasma Cell Proliferation in Multiple Myeloma Patients with 1q21 Amplification
2026-07-10
Sean Kaufman Faces Senate Scrutiny Over Past Vaccine Safety Comments Ahead of Confirmation Hearing
2026-07-10
Scroll to Top